X4 Pharmaceuticals, Inc.
XFOR
$3.31
$0.13164.14%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -101.98M | 14.60M | -37.45M | -16.76M | 17.63M |
Total Depreciation and Amortization | 1.37M | 1.21M | 796.00K | 585.00K | 422.00K |
Total Amortization of Deferred Charges | 832.00K | 827.00K | 856.00K | 903.00K | 952.00K |
Total Other Non-Cash Items | -1.57M | -123.61M | -97.78M | -106.50M | -132.78M |
Change in Net Operating Assets | -7.95M | -2.70M | 2.68M | -3.88M | 1.32M |
Cash from Operations | -109.30M | -109.67M | -130.90M | -125.65M | -112.45M |
Capital Expenditure | -133.00K | -267.00K | -326.00K | -320.00K | -236.00K |
Sale of Property, Plant, and Equipment | 0.00 | 105.00M | 105.00M | 105.00M | 105.00M |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -4.44M | -35.56M | -37.68M | -33.90M | -23.21M |
Cash from Investing | -4.58M | 69.17M | 66.99M | 70.78M | 81.55M |
Total Debt Issued | 0.00 | 20.00M | 20.00M | 20.00M | 42.50M |
Total Debt Repaid | -- | -- | -- | 0.00 | -764.00K |
Issuance of Common Stock | 5.77M | 294.00K | 294.00K | 256.00K | 256.00K |
Repurchase of Common Stock | -- | -- | -- | -- | -281.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | 0.00 | -250.00K |
Cash from Financing | 5.77M | 20.29M | 20.29M | 20.26M | 41.46M |
Foreign Exchange rate Adjustments | 132.00K | -25.00K | -156.00K | 215.00K | -22.00K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -107.97M | -20.23M | -43.77M | -34.40M | 10.54M |